A recent study demonstrated that lower levels of CD56bright NK cells in the CSF were associated with faster progression in ALS patients (Rolfes et al., 2021), thus supporting our results wherein a per standard deviation increase in CD16–CD56+ NK cells was found to be negatively associated with the risk of ALS. This evidence concerns the gene NCAM1 and amyotrophic lateral sclerosis.